FGL / FGLL
NCAM mimetic / FG loop peptide
- Molecular form
- Peptide motif with variant constructs
Peptide motif with variant constructs
Open the sources to check how the studies were done and what they can support.
An NCAM-derived peptide family with preclinical research and an early human FGLL tolerability and pharmacokinetic study.
- Family
- Neural cell adhesion molecule mimetic
- Research target
- NCAM / FGFR-associated signaling
- Molecular form
- Peptide motif with variant constructs
What to know about the research
The healthy-volunteer trial measured tolerability and exposure. It did not test treatment efficacy in Alzheimer’s disease.
Check the exact compound
The human study used intranasal FGL(L). Match that preparation before applying its findings to another construct.
What supports this entry?
3 of 3 summary statements linked to checked source passages.
These are selected references, not a complete review of the literature. Source checks were assisted by AI and have not received independent expert review.
Research stage, study quality and regulatory status answer different questions. A study card does not establish treatment benefit or approval.
Check the overview statementSource checked
An NCAM-derived peptide family with preclinical research and an early human FGLL tolerability and pharmacokinetic study.
Abstract: Background, Objective, Methods and Results
- Selected primary-source passages checked with AI assistance. Scope cautions are editorial interpretations; this is not a complete literature review.
Check the evidence limitationSource checked
The healthy-volunteer trial measured tolerability and exposure. It did not test treatment efficacy in Alzheimer’s disease.
Abstract: Background, Objective, Methods and Results
- Selected primary-source passages checked with AI assistance. Scope cautions are editorial interpretations; this is not a complete literature review.
Check the identity statementSource checked
The human study used intranasal FGL(L). Match that preparation before applying its findings to another construct.
Abstract: Background, Objective, Methods and Results
- Selected primary-source passages checked with AI assistance. Scope cautions are editorial interpretations; this is not a complete literature review.
Inside the selected studies
Open-label phase I ascending-dose study
Intranasal FGL(L)
- Who or what was studied
- Healthy male volunteers
- Sample size
- 24
- Compared with
- No placebo group described; sequential dose cohorts
- Duration
- 8 days
- Tolerability and pharmacokinetics; no Alzheimer’s treatment endpoint.
- Selected study only; source mapping is not independent study-quality appraisal.
- The finding applies to this population, preparation and study design.